Rami Ahmad | Cancer Therapy | Best Researcher Award

Published on 15/10/202515/10/2025 by Oncology

Prof. Dr. Rami Ahmad | Cancer Therapy | Best Researcher Award

Senior Researcher | Czech Education and Scientific Network | Czech Republic

Prof. Dr. Rami Ahmad El-Nabulsi is a distinguished theoretical physicist and applied mathematician whose research bridges nonlinear quantum dynamics, fractal mechanics, plasma and solid-state physics, and advanced mathematical modeling. Holding a PhD in Particle and Mathematical Physics from AMU, along with postgraduate diplomas in Plasma Physics and degrees in Physics at both master’s and bachelor’s levels, he has built a prolific career combining theoretical rigor with computational innovation. He is currently affiliated with the Center of Excellence in Quantum Technology, Faculty of Engineering, and the Quantum-Atom Optics Laboratory at Chiang Mai University, Thailand, as well as with the University of South Bohemia and the Department of Optical Networks CESNET in the Czech Republic. Prof. El-Nabulsi’s research interests encompass geometrical and quantum dynamics, nonlinear systems, chaos and bifurcations, general relativity, quantum field theory, and the application of fractional and fractal calculus to complex systems in engineering, astrophysics, and materials science. His expertise extends to advanced computational modeling, partial differential equations, stochastic systems, and numerical simulations. He has received multiple international honors, including the Outstanding Scientist Research Award and the Lifetime Achievement Award. A reviewer for more than 250 scientific journals and an editorial board member in over 40 peer-reviewed publications, he has authored more than 390 research articles in high-impact international journals and is frequently invited as an honorary speaker at global conferences. Prof. El-Nabulsi’s academic dedication, multidisciplinary approach, and sustained research excellence continue to shape theoretical and applied physics worldwide. His scholarly impact is reflected in 4,873 citations, 277 documents, and an h-index of 35, underscoring his influential role in advancing modern fractal physics and nonlinear dynamical systems research.

Profiles: Google Scholar | Scopus | ORCID

Featured Publications

1. El-Nabulsi, R. A., & Anukool, W. (2025). Chaotic and fractal maps in higher-order derivative dynamical systems. Frontiers in Physics, 12, 1529644. Cited by: 8

2. El-Nabulsi, R. A., & Anukool, W. (2025). Qualitative financial modelling in fractal dimensions. Financial Innovation, 11, 42. Cited by: 6

3. El-Nabulsi, R. A. (2025). A fractional model to study soliton in presence of charged space debris at low-Earth orbital plasma region. IEEE Transactions on Plasma Science, 52(9), 4671–4693. Cited by: 4

4. El-Nabulsi, R. A., & Golmankhaneh, A. K. (2025). Propagation of waves in fractal spaces. Waves in Random and Complex Media. Cited by: 4

5. El-Nabulsi, R. A., & Anukool, W. (2025). Vlasov equation, waves and dispersion relations in fractal dimensions: Landau damping and the toroidal ion temperature gradient instability problem. Waves in Random and Complex Media. Cited by: 14

6. El-Nabulsi, R. A. (2024). Transition from circular to spiral waves and from Mexican hat to upside-down Mexican hat-solutions: The cases of local and nonlocal λ–ω reaction–diffusion–convection fractal systems with variable coefficients. Chaos, Solitons & Fractals, 189, 115737. Cited by: 3

7. El-Nabulsi, R. A. (2024). Modelling nematic liquid crystal in fractal dimensions. Medicine in Novel Technology and Devices, 24, 100334. Cited by: 7

Yingxue Jin | Pharmaco-Oncology | Excellence in Oncology Research Award

Published on 24/03/202524/03/2025 by Oncology

Prof. Dr. Yingxue Jin | Pharmaco-Oncology | Excellence in Oncology Research Award

Harbin Normal University | China

AUTHOR PROFILE

Scopus

🧑‍🏫 YINGXUE JIN – PROFESSIONAL PROFILE

🎓 EARLY ACADEMIC PURSUITS

Yingxue Jin embarked on his academic journey with a strong foundation in science, eventually earning a Doctor of Science degree from Pusan National University in Korea in 2003. His academic background laid the groundwork for his expertise in pharmaceutical engineering and drug design. During his doctoral studies, he specialized in small molecule cyclic peptide drugs and nanodrug delivery systems, establishing a solid base for his future research contributions.

💼 PROFESSIONAL ENDEAVORS

Yingxue Jin has accumulated over three decades of experience in academia and research, holding key positions in prestigious institutions and companies:

Professor at Jiamusi University (1990 – 1999): Contributed to teaching and research in pharmaceutical sciences.
Senior Researcher at Korea Ilshin Chemical Company (2003 – 2004): Engaged in advanced chemical research, expanding his expertise in molecular synthesis.
Postdoctoral Researcher at Taiwan University, China (2005 – 2006): Conducted postdoctoral studies, refining his knowledge in pharmaceutical engineering and drug delivery mechanisms.
Professor at Harbin Normal University, China (2006 – Present):
- Serving as Head of the Department of Pharmaceutical Engineering.
- Director of Heilongjiang Chemical Society of China, promoting chemical science advancements.
- Awarded the honorary title of “Famous Teacher” at Harbin Normal University, recognizing his excellence in education and mentorship.

🔬 CONTRIBUTIONS AND RESEARCH FOCUS ON PHARMACO-ONCOLOGY

Yingxue Jin’s primary research interests revolve around:

Design and Synthesis of Small Molecule Cyclic Peptide Drugs: Developing novel peptide-based therapeutic agents for various diseases, including cancer.
Anti-Tumor Nanodrug Delivery Systems: Innovating targeted drug delivery methods to enhance the efficacy and precision of cancer treatments.
Project Leadership:
- Presided over two projects funded by the Natural Science Foundation of China (NSFC).
- Led the implementation of one key project and two general projects under the Natural Science Foundation of Heilongjiang Province, China.
- Supervised three natural science projects for the Heilongjiang Provincial Education Department, China.

🏅 IMPACT AND INFLUENCE

Yingxue Jin’s impactful contributions have been widely recognized through multiple awards and honors:

Natural Science and Technology Award of Heilongjiang Province: Acknowledging his significant scientific achievements.
Science and Technology Award of Heilongjiang Provincial Education Department: Recognizing his contributions to technological advancements in education.
Teaching Quality Award at Harbin Normal University (Multiple Occasions): Honoring his dedication to educational excellence and mentorship.

📚 ACADEMIC CITATIONS

Throughout his career, Yingxue Jin’s research has been widely cited in scientific publications, reflecting the influence and relevance of his work in the fields of pharmaceutical sciences, chemical engineering, and nanomedicine. His contributions have been referenced in numerous peer-reviewed journals, further establishing his reputation as a leading researcher in his field.

🌍 LEGACY AND FUTURE CONTRIBUTIONS

Yingxue Jin’s legacy is marked by his dedication to scientific innovation, educational mentorship, and pharmaceutical advancements. Moving forward, he aims to:

Expand his research in nanodrug delivery systems, focusing on precision medicine for oncology applications.
Foster collaborations with international research institutions to drive cross-disciplinary advancements.
Continue mentoring the next generation of scientists, contributing to the development of future leaders in pharmaceutical sciences.

🛡️ KEY ACHIEVEMENTS AND RECOGNITION

Honorary Title: Famous Teacher of Harbin Normal University.
Leadership Roles: Head of the Department of Pharmaceutical Engineering and Director of Heilongjiang Chemical Society of China.
Award-Winning Scientist: Recipient of multiple science and technology awards.
Renowned Educator: Consistently recognized for outstanding teaching quality.

🚀 CONCLUSION

Yingxue Jin’s extensive experience, innovative research, and dedication to scientific excellence and education have positioned him as a distinguished figure in the field of pharmaceutical sciences. His continued contributions to nanodrug delivery systems and cyclic peptide drug design are paving the way for groundbreaking advancements in cancer treatment and precision medicine.

📊🔬NOTABLE PUBLICATION:

1️⃣ Exploring the Potential of Cyclic Peptidyl Antitumor Agents Derived from Natural Macrocyclic Peptide Phakellistatin 13

Authors: Tong T. Li, Shitian S. Jiang, Tingting T. Li, Yingxue Y. Jin, Zhiqiang Z. Wang
Journal: Journal of Medicinal Chemistry
Year: 2024

2️⃣ Enhanced Catalytic Activity of Fe3O4-Carbon Dots Complex in the Fenton Reaction for Enhanced Immunotherapeutic and Oxygenation Effects

Authors: Guanghao G. Li, Yujun Y. Bao, Hui H. Zhang, Zhiqiang Z. Wang, Yingxue Y. Jin
Journal: Journal of Colloid and Interface Science
Year: 2024

3️⃣ A Novel Nanomedicine Integrating Ferroptosis and Photothermal Therapy, Well-Suitable for PD-L1-Mediated Immune Checkpoint Blockade

Authors: Yujun Y. Bao, Guanghao G. Li, Siqi S. Li, Changhong C. Guo, Yingxue Y. Jin
Journal: Materials Today Bio
Year: 2024

4️⃣ Targeted Delivery of Rhein via Hyaluronic Acid Modified Liposomes for Suppression of Growth and Metastasis of Breast Cancer

Authors: Jingchun J. Wang, Dijing D. Fan, Defu D. Cai, Yingxue Y. Jin
Journal: International Journal of Biological Macromolecules
Year: 2024

5️⃣ DFT-Aided Stereo-Structural and Electronic Structure Studies of Poly-Hydroxyl Substituted Chlorophyllous Molecules

Authors: Xiong X. Zhang, Tingting T. Li, Qi Q. Wang, Wen W. Fang, Zhiqiang Z. Wang
Journal: Computational and Theoretical Chemistry
Year: 2024

Prof. Linghua Li | Cancer Science | Best Researcher Award

Published on 16/12/202416/12/2024 by Oncology

Prof. Linghua Li | Cancer Science | Best Researcher Award

Guangzhou Eighth People’s Hospital | China

Author Profile

ORCID ID

🌟Linghua Li, Ph.D., M.S., B.S. 🌍

Head Director, Infectious Disease Center
Guangzhou Eighth People’s Hospital, Guangzhou Medical University

👩‍⚕️Biography

Dr. Linghua Li is a distinguished physician and researcher specializing in HIV/AIDS, infectious diseases, and oncology. With over 25 years of clinical experience, she has made significant contributions to understanding and managing infectious diseases, particularly fungal infections and HIV-related complications.

Dr. Li began her academic journey at the Medical School of Peking University, earning a B.S. in Clinical Medicine in 1997. She then pursued advanced studies at Sun Yat-sen University, completing an M.S. in Internal Medicine in 2008 and a Ph.D. in Infectious Diseases in 2011. She further enriched her expertise through visiting scholar positions at UNC-Chapel Hill (2012) and Duke University (2014), focusing on infectious diseases.

As the Head Director of the Infectious Disease Center at Guangzhou Eighth People’s Hospital, Dr. Li oversees clinical trials, patient care, and research initiatives for people living with HIV and at-risk populations. She has been principal investigator (PI) or co-investigator (Co-I) on more than 20 domestic and international research programs. Notable projects include:

National Natural Science Foundation of China (Grant No. 81301480): Investigating the mechanism and function of Phospholipase B in the growth and pathogenicity of P. marneffei.
Guangdong Natural Science Foundation (Grant No. 10151006002000000): Exploring the role of Phospholipase B in P. marneffei invasion of macrophages in AIDS patients.
NIH Fogarty Program: Examining host factors in severe opportunistic complications of AIDS, with a focus on developing targeted prophylactic strategies.

In recent years, Dr. Li has been a Co-PI on groundbreaking HIV PrEP Phase IV clinical trials in Guangzhou, including:

ChiCTR2100048981 and NCT04754139: These studies focus on scaling PrEP access for key populations in China. The trial successfully enrolled 1,007 participants by 2023, with 950 already on PrEP, marking it as the largest trial of its kind in China.

Dr. Li’s work emphasizes translational medicine, data-driven public health strategies, and the implementation of novel interventions like PrEP to curb HIV transmission. Her expertise in site coordination, implementation, data collection, and analysis has been pivotal to these efforts.

🧬Key Areas of Expertise

🔬 HIV Prevention and Treatment
🌿 Opportunistic Infections
📊 Clinical Trials and Data Analysis
🧑‍⚕️ Internal and Infectious Diseases

📚Academic Background

B.S., Clinical Medicine, Medical School of Peking University (1997)
M.S., Internal Medicine, Sun Yat-sen University (2008)
Ph.D., Infectious Diseases, Sun Yat-sen University (2011)
Visiting Scholar, UNC-Chapel Hill (2012)
Visiting Scholar, Duke University (2014)

🔬Research Impact

🌟 Over 20 funded research projects
📄 Numerous publications in infectious disease and public health journals
📚 Active contributor to advancing HIV prevention strategies in China

Dr. Linghua Li remains a leader in the fight against infectious diseases, with a career dedicated to improving global health outcomes. 🌏✨

✨ Conclusion

Dr. Linghua Li’s career exemplifies dedication to advancing the prevention, treatment, and understanding of infectious diseases, particularly HIV/AIDS and associated complications. Through her leadership, innovative research, and clinical expertise, she has significantly impacted global health, especially in developing effective interventions like PrEP for key populations in China. Her contributions to translational medicine and public health continue to pave the way for breakthroughs in managing infectious diseases and improving the lives of those affected worldwide. 🌟🌍

Assoc Prof Dr. RAFİYE CİFTCİLER – Targeted Cancer Therapy – Best Review Article Award

Published on 15/02/202415/02/2024 by Oncology

Assoc Prof Dr. RAFİYE CİFTCİLER - Targeted Cancer Therapy - Best Review Article Award

SELCUK UNIVERSITY FACULTY OF MEDICINE DEPARTMENT OF HEMATOLOGY -Turkey

AUTHOR PROFILE

Scopus

Orcid

Google Scholar

EARLY ACADEMIC PURSUITS:

Rafıye Ciftciler embarked on her academic journey with a strong foundation in medicine and a focus on hematology. She pursued her Medical School education at Hacettepe University Faculty of Medicine, where she laid the groundwork for her future contributions to the field.

PROFESSIONAL ENDEAVORS:

Following her medical education, Rafıye Ciftciler delved into Internal Medicine at Gazi University Faculty of Medicine, broadening her clinical expertise. Subsequently, she specialized in Hematology at Hacettepe University Faculty of Medicine, honing her skills in the intricate field of blood disorders.

CONTRIBUTIONS AND RESEARCH FOCUS ON TARGETED CANCER THERAPY

Rafıye Ciftciler has significantly contributed to the science of hematology, with approximately 100 publications to her name. Her research encompasses a diverse range of topics within hematology, showcasing her dedication to advancing knowledge in the field.

IMPACT AND INFLUENCE:

Her impact extends beyond publications, as evidenced by her accolades. The Young Researcher Award from the Turkish Society of Hematology at the 44th National Hematology Congress and the Oral Presentation Award at the 3rd National Blood and Bone Marrow Transplant Congress underscore her influence in the academic and scientific community.

ACADEMIC CITES:

Rafıye Ciftciler's work has likely garnered attention within the academic community, reflected in her certifications from esteemed organizations like the European Hematology Association and the Turkish Hematology Association. These certifications affirm her proficiency and recognition in the broader scientific arena.

LEGACY AND FUTURE CONTRIBUTIONS:

As an Associate Professor in the Department of Hematology at Selcuk University Faculty of Medicine, Rafıye Ciftciler has already established a commendable legacy. Her continuous contributions to the science of hematology and her role in shaping the next generation of medical professionals mark her as a key figure in the field.

HIGHLIGHT OF FUTURE CONTRIBUTIONS:

Looking ahead, Rafıye Ciftciler's future contributions are anticipated to further enrich the field of Targeted Cancer Therapy. Whether through groundbreaking research, mentorship, or educational initiatives, her commitment to advancing knowledge and improving patient care is poised to leave a lasting impact on the discipline.

NOTABLE PUBLICATIONS

Efficacy and Safety of Immune Checkpoint Inhibitors in Hematologic Malignancies. 2024

The Effect of Obesity and Body Mass Index on Hematologic Malignancies. 2023

Hereditary thrombocytopenia with familial novel mutation in MYH9 gene: A familial case report. 2023

Immune Thrombotic Thrombocytopenic Purpura in Elderly Patients: The Roles of PLASMIC and French Scores. 2023